PRSS22 as a novel prognostic and immune regulatory biomarker in PanCancer multiomics analysis.

ABSTRACT: Serine proteases are key mediators of tumorigenesis; however, the pan-cancer significance of PRSS22 remains poorly defined. This study comprehensively analyzes the multi-omics landscape and clinical relevance of PRSS22 across 33 cancer types using data from TCGA, HPA, and cBioPortal. We performed systematic analyses, including expression profiling (cancer vs. normal), prognosis (overall survival), characterization of the immune microenvironment, functional enrichment, and assessment of genomic alterations. PRSS22 expression demonstrated significant cancer-type specificity, with frequent overexpression observed in 10 cancer types and downregulation in 4 cancer types (p < 0.05). Notably, elevated tumor expression levels of PRSS22 were independently associated with worse overall survival in m

SUBMITTER: Jiang T 

PROVIDER: S-EPMC12644483 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature